Use of the Certificate for Pharmaceutical Products (CPP) in 18 Maturing Pharmaceutical Markets: Comparing Agency Guidelines with Company Practice
Tóm tắt
The certificate of pharmaceutical product (CPP) was implemented to accelerate the availability of new drugs in developing countries by providing evidence of the quality of products and reducing the time to market through reliance on a prior trusted analysis. However, the CPP format, issuing process and use have not been revised since 1997 and there are significant differences among countries in regard to requirements for CPP timing, terminology, and format. We sought to determine current CPP practices versus national regulatory guidelines and to inform recommendations for the efficient use of the CPP based on the needs of the modern regulatory environment. We conducted a comparative analysis of company practice versus agency guidelines across 18 maturing pharmaceutical markets using data from the Cortellis for Regulatory Intelligence® (CRI) and the Centre for Innovation in Regulatory Science (CIRS) Emerging Markets Regulatory Review Times (EMaRReT) databases and regulatory authorities’ websites. Of the studied 18 countries, 16 require the CPP for submission of new registrations; many accept alternative documentation but most still require legalization of the CPP and many are not compliant with the complex CPP format. Additional complicating factors include language requirements and varying local guidelines for CPP submission timing and validity dates. With the implementation of a number of suggested improvements, the CPP can continue to serve an important role in streamlining regulatory efficiency and provide confidence in new medicines, ensuring a more efficient and effective approval process and expediting patient access to safe and effective medicines worldwide.
Tài liệu tham khảo
World Health Organization. Use of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce. EDM Research Series. 1995; No. 016.
Withing E. How has the evolution of global pharmaceutical market affected the use of WHO Certificates for Pharmaceutical Product (CPP)? Reg Rapporteur. 2012;9:14–6.
World Health Organization. Quality control of drugs. In: Twenty-second World Health Assembly: Boston, Massachusetts, 8–25 July 1969: part I: resolutions and decisions: annexes. 1969: 99–105.
World Health Organization. Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce. In: Twenty-eighth World Health Assembly, Geneva, 13–30 May 1975. Part 1: Resolutions and decisions, annexes. 1975; 94–95.
World Health Organization. WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce. In: Forty-first World Health Assembly, Geneva, 2–13 May 1988. Resolutions and decisions, annexes. 1988; 53–55
World Health Organization. Proposed guidelines for implementation of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce. In: Forty-fifth World Health Assembly, Geneva, 4–14 May 1992. Resolutions and decisions, annexes. 1992; 155–165.
World Health Organization. Guidelines for implementation of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce. In: Forty-fifth World Health Assembly, Geneva, 5–14 May 1997. Resolutions and decisions, annexes. 1997; 2–3.
Davidson A, Grace AJ, Schwarz EW, Vicks C. Registration of medicinal products. Ther Innov Reg Sci. 2003;36:163–7.
Gebauer M. The Certificate of Pharmaceutical Product. Industry perspective. Presented at the International Federation of Pharmaceutical Manufacturers and Associations meeting, Kuala Lumpur, Malaysia, 2008.
World Health Organization. Proposal for revision of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce. Draft for comment, 2018. Available at https://www.who.int/medicines/areas/quality_safety/quality_assurance/28_06_2018_who_certification_scheme_qas18_768_rev1.pdf. Accessed October 29, 2019.
Sahl A. Thesis: Relevance of a certificate of pharmaceutical product for registration and life cycle management of imported drugs. How is the WHO certification scheme implemented by national health authorities outside of the ICH? 2013. Available at https://dgra.de/media/pdf/studium/masterthesis/master_sahl_a.pdf. Accessed October 29, 2019.
Wileman H, Mishra A. Drug lag and key regulatory barriers in the emerging markets. Perspect Clin Res. 2010;1:51–6.
Ndomondo-Sigonda M. WHO Certification Scheme for finished pharmaceutical products—Where are we today? Presented at the 13th International Conference of Drug Regulatory Authorities (ICDRA), 2008. Bern, Switzerland.
Diaz C, Perlow J, Sabeh L, Morales L. Concept and rules comparison for: CPPs, origin country, reference country in Latin America. SINDUSFARMA Working Group Regulatory LATAM. 2017. Available at https://sindusfarma.org.br/cadastro/public/uploads/legislacao/Boletim_DAR_Regulatory_Latam_05dez17.pdf Accessed October 29, 2019.
International Federation of Pharmaceutical Manufacturers and Associations. Position on the use of a Certificate of Pharmaceutical Product (CPP). 2018. Available at https://www.ifpma.org/wp-content/uploads/2018/05/CPP-Position-paper_17Aug_vF.pdf Accessed October 29, 2019.
Luwis C, Freitas M. PANDRH Project update: Assessing CPP requirements for medicines registration—presentation of the preliminary outcomes. IX CPANDRH. San Salvador, El Salvador. 2018. Available at https://www.paho.org/hq/index.php?option=com_docman&view=download&category_slug=ix-cpandrh&alias=47017-pandrh-project-update-assessing-cpp-requirement-for-medicines-registration-presentation-of-the-preliminary-outcomes-c-luwis-m-freitas&Itemid=270&lang=en Accessed October 29, 2019.
Prat AG. A practical overview of requirements for drug registration in Latin America. Reg Rapporteur. 2013;10(9):5–11.
Liberti L, McAuslane N, Patel P. CIRS R&D Briefing 51—Influencers of Lag Time in the Emerging Markets.
Diario Oficial de la Federación (DOF) of Mexico. Article 167 of the Regulation of Health Sector Products, 03-Feb-1998 as last amended.
European Medicines Agency. Certifying medicinal products. Available at https://www.ema.europa.eu/en/human-regulatory/post-authorisation/certifying-medicinal-products . Accessed 25 September 2019.
US FDA. General Certificates of Pharmaceutical Product Information Available at https://www.fda.gov/drugs/import-export-compliance-branch-iecb/general-certificates-pharmaceutical-product-information . Accessed 25 September 2019.
Hirako M, McAuslane N, Salek S. A Comparison of the drug review process at five international regulatory agencies. Drug Info J. 2007;41:291–308.
International Federation of Pharmaceutical Manufacturers and Associations. Modernization of the Certificate of Pharmaceutical Product (CPP) process: Facts and vision. 2016. Available at https://www.ifpma.org/wp-content/uploads/2018/05/Final-Position-ElectronicCPP_formated-July-2016.pdf Accessed October 29, 2019.
World Health Organization. WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce. Questions and Answers. (Q & A). Available at https://www.who.int/medicines/areas/quality_safety/regulation_legislation/certification/qas_certif_scheme_2011.pdf Accessed May 11, 2020.
McAuslane N, Walker S, Liberti L, Connelly P. Workshop report: Practical implementation of reliance models: What are the barriers and facilitators to the successful application of these models for innovative medicines, generics and variations? 2018; Sandton, South Africa. Available at https://www.cirsci.org/wp-content/uploads/2019/05/CIRS-March-2018-Workshop-report_15March18U15884.pdf Accessed October 29, 2019.
Patel P, McAuslane N, Liberti L, Connelly P. Workshop report: Facilitating the review of new medicines through risk-based evaluations: How can a stratification process be utilised to achieve an effective use of resources? 2017; Sao Paulo, Brazil. Available at https://www.cirsci.org/wp-content/uploads/2018/01/CIRS-March-2017-Workshop-Report_August-2017.pdf Accessed October 29, 2019.
Jain M. Quality certificates for small molecule drug product applications for international regulatory submissions. Reg Focus. 2017; May.
European Federation of Pharmaceutical Industries and Associations. White paper on reliance and expedited registration pathways in emerging markets. 2017. Available at https://www.efpia.eu/media/288592/white-paper-on-reliance-and-expedited-registration-pathways-in-emerging-markets.docx Accessed October 29, 2019.
Chong, SSF, Lim JCW, Tominaga T, Siaw S, Chong F, Lim J, Tominaga T (2018) Developing key performance indicators to measure the progress of regional regulatory convergence and cooperation in Asia Pacific Economic Co-operations (APEC). AAPS Open 4:4